Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Aug 1;114(5):397-403.
doi: 10.1161/CIRCULATIONAHA.106.628347. Epub 2006 Jul 24.

Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial

Ali Ahmed  1 , Michael W Rich, Jerome L Fleg, Michael R Zile, James B Young, Dalane W Kitzman, Thomas E Love, Wilbert S Aronow, Kirkwood F Adams Jr, Mihai Gheorghiade
Affiliations
Randomized Controlled Trial

Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial

Ali Ahmed et al. Circulation. .

Abstract

Background: About half of the 5 million heart failure patients in the United States have diastolic heart failure (clinical heart failure with normal or near-normal ejection fraction). Except for candesartan, no drugs have been tested in randomized clinical trials in these patients. Although digoxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Investigation Group ancillary trial, detailed findings from this important study have not previously been published.

Methods and results: Ambulatory chronic heart failure patients (n = 988) with normal sinus rhythm and ejection fraction > 45% (median, 53%) from the United States and Canada (1991 to 1993) were randomly assigned to digoxin (n = 492) or placebo (n = 496). During follow-up with a mean length of 37 months, 102 patients (21%) in the digoxin group and 119 patients (24%) in the placebo group (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.63 to 1.07; P = 0.136) experienced the primary combined outcome of heart failure hospitalization or heart failure mortality. Digoxin had no effect on all-cause or cause-specific mortality or on all-cause or cardiovascular hospitalization. Use of digoxin was associated with a trend toward a reduction in hospitalizations resulting from worsening heart failure (HR, 0.79; 95% CI, 0.59 to 1.04; P = 0.094) but also a trend toward an increase in hospitalizations for unstable angina (HR, 1.37; 95% CI, 0.99 to 1.91; P = 0.061).

Conclusions: In ambulatory patients with chronic mild to moderate diastolic heart failure and normal sinus rhythm receiving angiotensin-converting enzyme inhibitor and diuretics, digoxin had no effect on natural history end points such as mortality and all-cause or cardiovascular hospitalizations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier plots for (a) primary combined outcome of hospitalization due to worsening heart failure or mortality due to heart failure, and (b) combined outcome of hospitalization due to worsening heart failure or mortality due to cardiovascular causes, in diastolic heart failure patients randomized to receive digoxin or placebo (The number of patients at risk at each 12-month interval is shown below the figure)
Figure 2
Figure 2
Kaplan-Meier plots for mortality due to (a) all causes, (b) cardiovascular causes, and (c) heart failure, in diastolic heart failure patients randomized to receive digoxin or placebo (The number of patients at risk at each 12-month interval is shown below the figure)
Figure 2
Figure 2
Kaplan-Meier plots for mortality due to (a) all causes, (b) cardiovascular causes, and (c) heart failure, in diastolic heart failure patients randomized to receive digoxin or placebo (The number of patients at risk at each 12-month interval is shown below the figure)
Figure 3
Figure 3
Kaplan-Meier plots for hospitalization due to (a) all causes, (b) cardiovascular causes, and (c) worsening heart failure, in diastolic heart failure patients randomized to receive digoxin or placebo (The number of patients at risk at each 12-month interval is shown below the figure)
Figure 3
Figure 3
Kaplan-Meier plots for hospitalization due to (a) all causes, (b) cardiovascular causes, and (c) worsening heart failure, in diastolic heart failure patients randomized to receive digoxin or placebo (The number of patients at risk at each 12-month interval is shown below the figure)
See this image and copyright information in PMC

Comment in

References

    1. American Heart Association. Heart disease and stroke statistics — 2005 update. Dallas, Texas: 2005.
    1. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001 Aug 14;104(7):779–782. - PubMed
    1. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999 Jun;33(7):1948–1955. - PubMed
    1. Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002 Oct 15;137(8):631–639. - PubMed
    1. Redfield MM, Jacobsen SJ, Burnett JC, Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003 Jan 8;289(2):194–202. - PubMed

Publication types

MeSH terms